At the 2022 ASH, the PAN team presented an interim report from the Phase II clinical trial of donor-derived CD7 CAR T-cells for the treatment of R/R T-cell acute lymphoblastic leukemia/lymphoma (NCT04689659) (68). The gene discussed is CD7; the disease is lymphoma.